Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications -: The effect of α-tocopherol supplementation
Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications -: The effect of α-tocopherol supplementation
复制标题
DOI：
10.1161/01.cir.102.2.191
复制
发表时间：
2000-07-11
期刊：
影响因子：
37.8
通讯作者：
Jialal, I
中科院分区：
文献类型：
--
作者：
Devaraj, S;Jialal, I
背景--尽管糖尿病可加速动脉粥样硬化形成，但与对照组相比，2型糖尿病伴（DM 2-MV）和不伴（DM 2）大血管病变患者的单核细胞活性缺乏数据。（糖化和氧化），单核细胞促动脉粥样硬化活性，并且可溶性细胞粘附分子（sCAM）的循环水平在DM 2-MV中比在DM 2和对照受试者中更显著，以及（2）RRR-alpha-生育酚（AT）治疗，1200 IU/d，持续3个月，在3组中具有相似的效果（每组n=25）。方法和结果-尽管与对照组相比，两个糖尿病组的LDL糖化增加，AT治疗对糖化没有显著影响，AT治疗在所有3组中显著降低LDL氧化能力。与对照组相比，糖尿病患者单核细胞释放的超氧阴离子（O-2（-））和白细胞介素-1 β（IL-1 β）显著增加，并表现出更强的内皮粘附性。AT治疗显著降低了所有3组中O-2（-）、IL-1 β、肿瘤坏死因子-α和单核细胞-内皮细胞粘附的释放。2个糖尿病组之间的上述任何参数均无显著差异。与对照组相比，两组sICAM水平均显著升高。AT治疗导致sCAMs.Conclusions-This是第一次证明增加IL-1 β分泌和增加单核细胞粘附内皮细胞从normocyanidemic糖尿病受试者和单核细胞活性降低和sCAMs与AT治疗糖尿病受试者和无大血管病变。
Background-Although diabetes confers an increased propensity toward accelerated atherogenesis, data are lacking on monocyte activity in typo 2 diabetic patients with (DM2-MV) and without (DM2) macrovascular disease compared with control subjects, Thus, we tested whether (1) postsecretory modifications of LDL (glycation and oxidation), monocyte proatherogenic activity, and circulating levels of soluble cell adhesion molecules (sCAMs) are more pronounced in DM2-MV than in DM2 and control subjects and (2) RRR-alpha-tocopherol (AT) therapy, 1200 IU/d for 3 months, has a similar effect in the 3 groups (n=25 per group).Methods and Results-Although LDL glycation was increased in both diabetic groups compared with control subjects, AT therapy had no significant effect on glycation, AT therapy significantly decreased LDL oxidizability in all 3 groups. Diabetic n monocytes released significantly more superoxide anion (O-2(-)) and interleukin-1 beta (IL-1 beta) and exhibited greater adhesion to endothelium than control subjects. AT therapy significantly decreased the release of O-2(-), IL-1 beta, tumor necrosis factor-alpha, and monocyte-endothelium adhesion in all 3 groups. There was no significant difference between the 2 diabetic groups for any of the above parameters. sICAM levels were significantly elevated in both diabetic groups compared with controls. AT therapy resulted in a significant decrease in sCAMs.Conclusions-This is the first demonstration of increased IL-1 beta secretion and increased adhesion of monocytes to endothelium from normotriglyceridemic diabetic subjects and of decreased monocyte activity and sCAMs with AT therapy in diabetic subjects with and without macrovasculopathy.